

CITATION REPORT

List of articles citing

A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19

DOI: 10.1056/nejmoa2021801

New England Journal of Medicine, 2021, 384, 417-427.

Source: <https://exaly.com/paper-pdf/77889982/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
158	Hydroxychloroquine in the post-COVID-19 era: will this pandemic upset decades of clinical practice?. 2021 , 40, 1649-1657		1
157	Hydroxychloroquine Plus Standard Personal Protective Equipment Versus Standard Personal Protective Equipment Alone for the Prevention of Laboratory Confirmed Covid-19 Infections Among Healthcare Workers: A Multi-Centre Parallel Group Randomized Controlled Trial from India. <i>SSRN Electronic Journal</i> ,	1	
156	Serosurvey for Health-Care Workers Provides Supportive Evidence for the Effectiveness of Hydroxychloroquine Prophylaxis against SARS-CoV-2 Infection. 2021 , 11, 283-288		2
155	Authors' response. 2021 , 153, 565-567		
154	Filling the Gap Until Full Vaccine Deployment in the War on Coronavirus Disease-19. 2021 , 10, 27-34		1
153	Therapeutic supplementation with zinc in the management of COVID-19-related diarrhea and ageusia/dysgeusia: mechanisms and clues for a personalized dosage regimen. 2021 ,		2
152	COVID-19 illness and autoimmune diseases: recent insights. 2021 , 70, 407-428		5
151	Understanding Viral Infection Mechanisms and Patient Symptoms for the Development of COVID-19 Therapeutics. 2021 , 22,		5
150	Gestione del Covid-19 in et� pediatrica: documento di consenso. 2021 , 40, 85-101		4
149	Self-Reported Symptoms in a Cohort of Rheumatoid Arthritis and Systemic Lupus Erythematosus during the COVID-19 Quarantine Period. 2021 , 15, 16-23		0
148	Incidence of COVID-19 in patients exposed to chloroquine and hydroxychloroquine: results from a population-based prospective cohort in Catalonia, Spain, 2020. 2021 , 26,		2
147	The WHO guideline on drugs to prevent COVID-19: small numbers- big conclusions. 2021 , 6, 71		1
146	COVID-19 in Brazil: A Message to the World. 2021 , 43, 238-239		1
145	A living WHO guideline on drugs to prevent covid-19. 2021 , 372, n526		31
144	COVID-19 in early 2021: current status and looking forward. 2021 , 6, 114		74
143	Una presentaci� infrecuente de COVID-19, con diarrea como s�toma inicial, el primer caso diagnosticado en Cartagena, Colombia.. 2021 , 10, 65-74		
142	Does hydroxychloroquine still have any role in the COVID-19 pandemic?. 2021 , 22, 1257-1266		4

141	Kidney transplantation and COVID-19 renal and patient prognosis. 2021 , 14, i21-i29	5
140	Post-exposure prophylaxis against SARS-CoV-2 in close contacts of confirmed COVID-19 cases (CORIPREV): study protocol for a cluster-randomized trial. 2021 , 22, 224	4
139	The first 12 months of COVID-19: a timeline of immunological insights. 2021 , 21, 245-256	140
138	Consensus Recommendations for Intramuscular COVID-19 Vaccination in Patients with Hemophilia. 2021 , 41, 190-196	2
137	Prophylaxis against covid-19: living systematic review and network meta-analysis. 2021 , 373, n949	31
136	COVID-19: Antiviral Tedavi.	
135	Evaluating alternative hypotheses to explain the downward trend in the indices of the COVID-19 pandemic death rate. 2021 , 9, e11150	1
134	Will the pill help defeat the coronavirus?. 2021 , 6, 001-005	
133	Risk of coronavirus disease 2019 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional disease-modifying anti-rheumatic drugs in Italy. 2021 , 60, S125-S136	5
132	Efficacy of a nasal spray containing Iota-Carrageenan in the prophylaxis of COVID-19 in hospital personnel dedicated to patients care with COVID-19 disease A pragmatic multicenter, randomized, double-blind, placebo-controlled trial (CARR-COV-02).	5
131	Assessing the efficacy and safety of hydroxychloroquine as outpatient treatment of COVID-19: a randomized controlled trial. 2021 , 9, E693-E702	7
130	The time to offer treatments for COVID-19. 2021 , 30, 505-518	9
129	COVID-19 Management in the Pediatric Age: Consensus Document of the COVID-19 Working Group in Paediatrics of the Emilia-Romagna Region (RE-CO-Ped), Italy. 2021 , 18,	13
128	Understanding the drivers of transmission of SARS-CoV-2. 2021 , 21, 580-581	2
127	Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial. <i>International Journal of Infectious Diseases</i> , 2021 , 106, 314-322 ^{10,5}	22
126	Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study. 2021 , 21, 629-636	168
125	Measuring the QT interval on the go. 2021 , 28, 358-359	
124	Quantifying the relationship between SARS-CoV-2 viral load and infectiousness.	4

123	A Pandemic within Other Pandemics. When a Multiple Infection of a Host Occurs: SARS-CoV-2, HIV and. 2021 , 13,	3
122	Estimating vaccine efficacy against transmission via effect on viral load.	3
121	Improving the Outcomes of Immunocompromised Patients With Coronavirus Disease 2019. 2021 , 73, e1397-e1401	17
120	Testing the feasibility of operationalizing a prospective, randomized trial with remote cardiac safety EKG monitoring during a pandemic. 2021 , 1	1
119	Mortality, viral clearance, and other clinical outcomes of hydroxychloroquine in COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials. 2021 , 14, 1101-1112	4
118	Remdesivir for Early COVID-19 Treatment of High-Risk Individuals Prior to or at Early Disease Onset-Lessons Learned. 2021 , 13,	5
117	National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. 2021 , 84, 1254-1268	42
116	Exploring insights of hydroxychloroquine, a controversial drug in Covid-19: An update. 2021 , 151, 112106	3
115	COVID-19 chemoprevention. <i>International Journal of Infectious Diseases</i> , 2021 , 107, 31-33	10.5
114	HIV and COVID-19: Lessons From HIV and STI Harm Reduction Strategies. 2021 , 18, 261-270	2
113	Impact of Prophylactic Hydroxychloroquine on People at High Risk of COVID-19: A Systematic Review and Meta-Analysis. 2021 , 10,	3
112	International Changes in COVID-19 Clinical Trajectories Across 315 Hospitals and 6 Countries: Retrospective Cohort Study. 2021 , 23, e31400	2
111	[SARS-CoV-2 infection: Available data on 15th April 2021]. 2021 , 38, 616-625	
110	International Changes in COVID-19 Clinical Trajectories Across 315 Hospitals and 6 Countries: a 4CE Consortium Study (Preprint).	
109	SARS-CoV-2 Antiviral Therapy. 2021 , e0010921	12
108	Prophylaxis Against COVID-19 With Hydroxychloroquine and Chloroquine: Comment on the Article by Putman et al. 2021 , 73, 1765-1767	
107	The Value of Medical Registries and Observational Studies Early in Pandemics: The COVID-19 Experience. 2021 ,	2
106	Hydroxychloroquine as a primary prophylactic agent against SARS-CoV-2 infection: A cohort study. <i>International Journal of Infectious Diseases</i> , 2021 , 108, 370-376	10.5 3

105	Treatment of COVID-19 in Patients With Sarcoidosis. 2021 , 8, 689539	1
104	Sales of antibiotics and hydroxychloroquine in India during the COVID-19 epidemic: An interrupted time series analysis. 2021 , 18, e1003682	29
103	Outpatient Management of COVID-19 Disease: A Holistic Patient-Centered Proposal Based on the Greek Experience. 2021 , 11,	1
102	How Brazil's President turned the country into a global epicenter of COVID-19. 2021 , 42, 439-451	11
101	Herzinsuffizienz und SARS-CoV-2. 2021 , 10, 351-354	
100	Evaluation of SARS-CoV-2 IgG antibody reactivity in patients with systemic lupus erythematosus: analysis of a multi-racial and multi-ethnic cohort. 2021 , 3, e585-e594	11
99	Updates on Hydroxychloroquine in Prevention and Treatment of COVID-19. 2021 ,	3
98	[Hydroxychloroquine: An Essential Drug in Dermatology and Its Controversial Use in COVID-19]. <i>Actas Dermo-sifiliográficas</i> , 2021 ,	0.5
97	SARS-CoV-2 Infection Modulates ACE2 Function and Subsequent Inflammatory Responses in Swabs and Plasma of COVID-19 Patients. 2021 , 13,	3
96	Electrophysiological and Proarrhythmic Effects of Hydroxychloroquine Challenge in Guinea-Pig Hearts. 2021 , 4, 1639-1653	0
95	Estimating Vaccine Efficacy Against Transmission via Effect on Viral Load. 2021 , 32, 820-828	3
94	Current status of therapeutic alternatives for COVID-19: A narrative review.. 2021 , 29, 312-327	2
93	Hydroxychloroquine inhibits proteolytic processing of endogenous TLR7 protein in human primary plasmacytoid dendritic cells.	
92	Hydroxychloroquine inhibits proteolytic processing of endogenous TLR7 protein in human primary plasmacytoid dendritic cells. 2021 ,	4
91	Clinical trials with antiviral drugs against COVID-19: some progress and many shattered hopes. 2021 , 23, 6364-6376	4
90	Design, Implementation, and Evaluation of a Distance Learning Framework to Adapt to the Changing Landscape of Anatomy Instruction in Medical Education During COVID-19 Pandemic: A Proof-of-Concept Study. 2021 , 9, 726814	0
89	The WHO guideline on drugs to prevent COVID-19: small numbers- big conclusions. 2021 , 6, 71	1
88	Quantifying the relationship between SARS-CoV-2 viral load and infectiousness. 2021 , 10,	20

87	Low dose hydroxychloroquine prophylaxis for COVID-19 in a prospective study.		
86	The future is now: our experience starting a remote clinical trial during the beginning of the COVID-19 pandemic. 2021 , 22, 603		1
85	Beyond Vaccines: Clinical Status of Prospective COVID-19 Therapeutics. <i>Frontiers in Immunology</i> , 2021 , 12, 752227	8.4	5
84	The utilization of hydroxychloroquine to reduce the main signs and symptoms of COVID-19 patients, a cross-sectional study. 2021 , 70, 102867		1
83	Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Postexposure Prophylaxis of COVID-19 in Hospital Personnel Dedicated to Patients Care with COVID-19 Disease. 2021 , 14, 6277-6286		14
82	Animal models of SARS-CoV-2 and COVID-19 for the development of prophylactic and therapeutic interventions. 2021 , 228, 107931		7
81	Interpreting the impact of hydroxychloroquine prophylaxis on SARS-CoV-2 infection. 2021 , 153, 564-565		
80	The efficacy and safety of hydroxychloroquine for COVID-19 prophylaxis: A systematic review and meta-analysis of randomized trials. 2021 , 16, e0244778		25
79	High SARS-CoV-2 load in the nasopharynx of patients with a mild form of COVID-19 is associated with clinical deterioration regardless of the hydroxychloroquine administration. 2021 , 16, e0246396		2
78	Role of Pegylated Interferon in Patients with Chronic Liver Diseases in the Context of SARS-CoV-2 Infection. 2021 , 11, 27-31		1
77	Effective post-exposure prophylaxis of Covid-19 is associated with use of hydroxychloroquine: Prospective re-analysis of a public dataset incorporating novel data.		2
76	Terapias farmacológicas para la COVID-19. 2021 , 19, 408-420		
75	Enfermedad por coronavirus 2019 (COVID-19). 2021 , 40, 41-49		
74	ACE2 and Innate Immunity in the Regulation of SARS-CoV-2-Induced Acute Lung Injury: A Review. 2021 , 22,		1
73	Comparative effectiveness of pharmacological interventions on mortality and the average length of hospital stay of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. <i>Expert Review of Anti-Infective Therapy</i> , 2021 ,	5.5	0
72	Immunopathological events surrounding IL-6 and IFN- γ bridge for anti-lupus erythematosus drugs used to treat COVID-19. 2021 , 101, 108254		2
71	Lessons Learned From Conducting Internet-Based Randomized Clinical Trials During a Global Pandemic. 2021 , 8, ofaa602		3
70	SARS-CoV-2 infection in heart transplant recipients: a systematic literature review of clinical outcomes and immunosuppression strategies. 2021 , 1		0

69	Systematic review and meta-analysis of the safety of chloroquine and hydroxychloroquine from randomized controlled trials on malarial and non-malarial conditions. 2021 , 10, 294		0
68	Efficacy and safety of chloroquine and hydroxychloroquine for treatment of COVID-19 patients-a systematic review and meta-analysis of randomized controlled trials. 2021 , 11, 93-107		9
67	Hydroxychloroquine treatment on SARS-CoV-2 receptor ACE2, TMPRSS2 and NRP1 expression in human primary pterygium and conjunctival cells. 2021 , 214, 108864		0
66	Hydroxychloroquine: An Essential Drug in Dermatology and Its Controversial Use in COVID-19. <i>Actas Dermo-sifiligráficas</i> , 2021 ,	0.5	
65	Ethical challenges of prospective clinical trials during the COVID-19 pandemic. <i>Expert Review of Anti-Infective Therapy</i> , 2021 , 1-6	5.5	
64	COVID-19: Update on Its Ocular Involvements, and Complications From Its Treatments and Vaccinations. 2021 , 10,		5
63	Model-Informed Drug Development Approaches to Assist New Drug Development in the COVID-19 Pandemic. <i>Clinical Pharmacology and Therapeutics</i> , 2021 ,	6.1	0
62	A comparison between virus- versus patients-centred therapeutic attempts to reduce COVID-19 mortality. 2021 , 10, 2256-2263		1
61	Mechanisms of action of fluvoxamine for COVID-19: a historical review.. 2022 ,		8
60	Cangma Huadu granules, a new drug with great potential to treat coronavirus and influenza infections, exert its efficacy through anti-inflammatory and immune regulation.. 2022 , 287, 114965		0
59	COVID-19 in der Neurologie: Das klinische Bild wird präziser.		1
58	Use of hydroxychloroquine to prevent SARS-CoV-2 infection and treat mild COVID-19: a systematic review and meta-analysis. <i>Jornal Brasileiro De Pneumologia</i> , 2021 , 47, e20210236	1.1	0
57	COVID-19: les thérapeutiques. 2022 , 1, 13-13		
56	Tafenoquine and its derivatives as inhibitors for the Severe Acute Respiratory Syndrome Coronavirus 2.. <i>Journal of Biological Chemistry</i> , 2022 , 101658	5.4	1
55	Hydroxychloroquine/Chloroquine for the Treatment of Hospitalized Patients with COVID-19: An Individual Participant Data Meta-Analysis.. 2022 ,		1
54	Hydroxychloroquine/Chloroquine in COVID-19 With Focus on Hospitalized Patients [A Systematic Review.		0
53	Safety and Tolerability of Hydroxychloroquine in healthcare workers and first responders for the prevention of COVID-19: WHIP COVID-19 Study.. <i>International Journal of Infectious Diseases</i> , 2021 ,	10.5	0
52	Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines.. <i>Annals of Medicine</i> , 2022 , 54, 524-540	1.5	17

51	A Prophylactic Community Based Study to Assess the Impact of Ayu Raksha Kit in COVID-19 □ Protocol of a Cluster Randomised Trial. <i>SSRN Electronic Journal</i> ,	1	
50	[Translated article] Hydroxychloroquine: An Essential Drug in Dermatology and Its Controversial Use in COVID-19.. <i>Actas Dermo-sifilograficas</i> , 2022 , 113, T166-T175	0.5	
49	Rationale and Design of the COVID-19 Outpatient Prevention Evaluation (COPE - Coalition V) Randomized Clinical Trial: Hydroxychloroquine vs. Placebo in Non-Hospitalized Patients.. <i>Arquivos Brasileiros De Cardiologia</i> , 2022 , 118, 378-387	1.2	1
48	Can anti-parasitic drugs help control COVID-19?. <i>Future Virology</i> , 2022 ,	2.4	1
47	Current challenges in different approaches to control COVID-19: a comprehensive review.. <i>Bulletin of the National Research Centre</i> , 2022 , 46, 47	3	0
46	Emergence, evolution, and vaccine production approaches of SARS-CoV-2 virus: benefits of getting vaccinated and common questions.. <i>Saudi Journal of Biological Sciences</i> , 2021 ,	4	0
45	Molnupiravir and Its Antiviral Activity Against COVID-19.. <i>Frontiers in Immunology</i> , 2022 , 13, 855496	8.4	10
44	Hydroxychloroquine versus placebo in the treatment of non-hospitalised patients with COVID-19 (COPE - Coalition V): A double-blind, multicentre, randomised, controlled trial.. <i>The Lancet Regional Health Americas</i> , 2022 , 11, 100243		0
43	Molecular Evolution of Severe Acute Respiratory Syndrome Coronavirus 2: Hazardous and More Hazardous Strains Behind the Coronavirus Disease 2019 Pandemic and Their Targeting by Drugs and Vaccines.. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021 , 11, 763687	5.9	1
42	Power and sample size calculations for cluster randomized trials with binary outcomes when intracluster correlation coefficients vary by treatment arm. <i>Clinical Trials</i> , 2021 , 17407745211059845	2.2	
41	Safety and efficacy of hydroxychloroquine for treatment of non-severe COVID-19 among adults in Uganda: a randomized open label phase II clinical trial. <i>BMC Infectious Diseases</i> , 2021 , 21, 1218	4	0
40	Hydroxychloroquine as pre-exposure prophylaxis against COVID-19 infection among healthcare workers: a prospective cohort study. <i>Expert Review of Anti-Infective Therapy</i> , 2021 ,	5.5	
39	Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease.. <i>Scientific Reports</i> , 2022 , 12, 4925	4.9	5
38	Assessment of porphyrogenicity of drugs and chemicals in selected hepatic cell culture models through a fluorescence-based screening assay.. <i>Pharmacology Research and Perspectives</i> , 2022 , 10, e00951 ¹	3.1	0
37	Hydroxychloroquine Causes Early Inner Retinal Toxicity and Affects Autophagosome-Lysosomal Pathway and Sphingolipid Metabolism in the Retina.. <i>Molecular Neurobiology</i> , 2022 , 1	6.2	0
36	Virological and Clinical Determinants of the Magnitude of Humoral Responses to SARS-CoV-2 in Mild-Symptomatic Individuals.. <i>Frontiers in Immunology</i> , 2022 , 13, 860215	8.4	0
35	A Review of the Ring Trial Design for Evaluating Ring Interventions for Infectious Diseases.. <i>Epidemiologic Reviews</i> , 2022 ,	4.1	
34	Safety of Short-Term Treatments with Oral Chloroquine and Hydroxychloroquine in Patients with and without COVID-19: A Systematic Review. <i>Pharmaceuticals</i> , 2022 , 15, 634	5.2	1

33	Efficacy of COVID-19 treatments among geriatric patients: a systematic review. <i>Therapeutic Advances in Infectious Disease</i> , 2022 , 9, 204993612210956	2.8	0
32	Pharmacometric and electrocardiographic evaluation of chloroquine and azithromycin in healthy volunteers. <i>Clinical Pharmacology and Therapeutics</i> ,	6.1	1
31	COVID 19 pandemic challenges and their management: A review of medicines, vaccines, patents and clinical trials with emphasis on psychological health issues. <i>Saudi Pharmaceutical Journal</i> , 2022 ,	4.4	0
30	Hydroxychloroquine plus personal protective equipment versus personal protective equipment alone for the prevention of laboratory-confirmed COVID-19 infections among healthcare workers: a multicentre, parallel-group randomised controlled trial from India. <i>BMJ Open</i> , 2022 , 12, e059540	3	1
29	Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences. <i>Vaccines</i> , 2022 , 10, 919	5.3	2
28	Changes in laboratory value improvement and mortality rates over the course of the pandemic: an international retrospective cohort study of hospitalised patients infected with SARS-CoV-2. <i>BMJ Open</i> , 2022 , 12, e057725	3	0
27	Interaction between Sars-CoV-2 structural proteins and host cellular receptors: From basic mechanisms to clinical perspectives. <i>Advances in Protein Chemistry and Structural Biology</i> , 2022 ,	5.3	
26	Antiparasitic Drugs against SARS-CoV-2: A Comprehensive Literature Survey. <i>Microorganisms</i> , 2022 , 10, 1284	4.9	1
25	Dimethoxycurcumin Acidifies Endolysosomes and Inhibits SARS-CoV-2 Entry. <i>Frontiers in Virology</i> , 2,		0
24	COVID-19 Infection in Renal Transplant Recipients at Dubai Hospital: Incidence, Clinical Profile, and Outcome. <i>Dubai Medical Journal</i> , 1-9	1.1	0
23	Polygenic autoimmune disease risk alleles impacting B cell tolerance act in concert across shared molecular networks in mouse and in humans. 13,		0
22	Evolution of Approaches to Therapeutic Prevention and Treatment of the New Coronavirus Infection. 2022 , 92, 430-436		0
21	Development of SARS-CoV-2 infection in patients with rheumatic conditions on hydroxychloroquine monotherapy vs. patients without rheumatic conditions: a retrospective, propensity-matched cohort study. 2022 ,		0
20	Identification of Suitable Drug Combinations for Treating COVID-19 Using a Novel Machine Learning Approach: The RAIN Method. 2022 , 12, 1456		0
19	Evolution of Care and Outcomes Across Surges in Hospitalized Patients with Coronavirus Disease 2019. 2022 ,		0
18	Hydroxychloroquine/chloroquine for the treatment of hospitalized patients with COVID-19: An individual participant data meta-analysis. 2022 , 17, e0273526		0
17	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19.		6
16	Care for adults with COVID -19: living guidelines from the National COVID -19 Clinical Evidence Taskforce. 2022 , 217, 368-378		1

- 15 Progress, pitfalls, and path forward of drug repurposing for COVID-19 treatment. **2022**, 16, 175346662211327 ○
- 14 Eventos adversos no sistema nervoso central potencialmente relacionados aos medicamentos utilizados na COVID-19: revisõ de escopo. **2022**, 46, 1 ○
- 13 Medications for early treatment of COVID -19 in Australia. ○
- 12 The failure of drug repurposing for COVID-19 as an effect of excessive hypothesis testing and weak mechanistic evidence. **2022**, 44, ○
- 11 Treatment and case fatality rate of COVID-19 in Africa. **2022**, 13, ○
- 10 Paxlovid accelerates cartilage degeneration and senescence through activating endoplasmic reticulum stress and interfering redox homeostasis. **2022**, 20, ○
- 9 Biologic Functions of Hydroxychloroquine in Disease: From COVID-19 to Cancer. **2022**, 14, 2551 ○
- 8 Failed Repurposing of Lysosomotropic Drugs for COVID-19 Treatment or Prevention. **2022**, 1, 22-28 ○
- 7 The Myth of Hydroxychloroquine (HCQ) as post-exposure prophylaxis (PEP) for the prevention of COVID-19s far from reality. **2023**, 13, ○
- 6 Hydroxychloroquine for treatment of non-hospitalized adults with COVID -19: A meta-analysis of individual participant data of randomized trials. ○
- 5 COVID-19 in patients with Systemic Lupus Erythematosus and the antiphospholipid syndrome. **2023**, 529-555 ○
- 4 Efficacy and safety of ivermectin in patients with mild and moderate COVID-19: A randomized controlled trial. **2023**, 16, 3 ○
- 3 The Efficacy and Safety of Hydroxychloroquine for COVID-19 Prophylaxis: Systematic Review and Meta-analysis (Preprint). ○
- 2 The development of COVID-19 treatment. 14, 2
- 1 Challenges Based on Antiplasmodial and Antiviral Activities of 7-Chloro-4-aminoquinoline Derivatives. **2023**, 18, ○